Acrux developed Dapsone 7.5%, Gel which was approved by the FDA in 2024 as an AB rated generic. The product is licensed for commercialisation to TruPharma. It was launched in the United States in May 2025.
Dapsone 7.5%, Gel is a prescription medicine used on your skin (topical) to treat acne vulgaris in children 9 years of age or older.
Refer to the Prescribing Information for further information on the product.